Marea heads to Phase 2b after updated biomarker data show CV drug’s promise

Elizabeth Cairns

Senior biopharma journalist

Marea Therapeutics said on Wednesday that its lipid-lowering antibody cut both remnant cholesterol levels and remnant triglycerides — both indicators for cardiovascular disease in at-risk patients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Marea heads to Phase 2b after updated biomarker data show CV drug’s promise

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Summit says bispecific misses overall survival in closely-watched lung cancer study

Summit’s disappointing survival readout raises stakes for full data

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech

Sanofi, Regeneron report underwhelming COPD data for IL-33 antibody, shares drop

As a challenging first half nears a close, biopharma uncertainty persists

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Marea heads to Phase 2b af­ter up­dat­ed bio­mark­er da­ta show CV drug’s promise

Senior biopharma journalist

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Marea heads to Phase 2b after updated biomarker data show CV drug’s promise